Aberdeen Group plc Sells 74,618 Shares of GRAIL, Inc. $GRAL

Aberdeen Group plc decreased its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 26.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 210,117 shares of the company’s stock after selling 74,618 shares during the quarter. Aberdeen Group plc owned 0.58% of GRAIL worth $10,804,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. KBC Group NV lifted its position in GRAIL by 187.7% during the first quarter. KBC Group NV now owns 1,430 shares of the company’s stock worth $37,000 after purchasing an additional 933 shares during the period. S.A. Mason LLC lifted its position in GRAIL by 50.1% during the first quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock worth $38,000 after purchasing an additional 500 shares during the period. Farther Finance Advisors LLC lifted its position in GRAIL by 768.1% during the second quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $42,000 after purchasing an additional 722 shares during the period. NewEdge Advisors LLC lifted its position in GRAIL by 390.3% during the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after purchasing an additional 1,401 shares during the period. Finally, Signaturefd LLC raised its stake in GRAIL by 273.0% during the first quarter. Signaturefd LLC now owns 1,876 shares of the company’s stock worth $48,000 after acquiring an additional 1,373 shares in the last quarter.

Analysts Set New Price Targets

GRAL has been the subject of several research analyst reports. UBS Group set a $75.00 target price on GRAIL in a research note on Friday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group boosted their target price on GRAIL from $43.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GRAIL has a consensus rating of “Hold” and an average price target of $56.67.

GRAIL Price Performance

GRAIL stock opened at $75.52 on Thursday. The business has a 50 day moving average of $44.22 and a 200-day moving average of $39.30. GRAIL, Inc. has a 1 year low of $12.76 and a 1 year high of $76.22. The company has a market capitalization of $2.72 billion, a P/E ratio of -5.76 and a beta of 4.11.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The firm had revenue of $35.54 million during the quarter, compared to analyst estimates of $37.57 million. Equities analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current year.

Insiders Place Their Bets

In other GRAIL news, President Joshua J. Ofman sold 81,385 shares of the stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $62.50, for a total transaction of $5,086,562.50. Following the completion of the sale, the president owned 396,797 shares of the company’s stock, valued at approximately $24,799,812.50. This represents a 17.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 95,279 shares of company stock worth $5,841,399. Corporate insiders own 1.85% of the company’s stock.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.